Skip To Main Content

Unmet needs in adults with T2D receiving premixed insulin

Suboptimal glycemic target achievement is common in people with T2D

  • In a meta-analysis of 24 studies across 20 countries: the proportion of people achieving HbA1c targets was 43%.1
  • According to the IDMPS: <50% of participants achieved a glycaemic goal of HbA1c <7% in LMICs2

Real-world evidence shows poor glycemic control with premix

<20%: UK THIN: <20% achieved HbA1c <7.5% 24 months after initiating with premix insulin3

∼20%: IDMPS: ~20% on premix insulin reached HbA1c <7% in LMICs4

>28%: CoDiC: >28% had their HbA1c >8% for 17 months after switching from BI to premix insulin5

Many people with T2D eventually require injectable therapy.6-8

Globally, 30% of people with T2D use premix insulin9, but this is associated with:

Greater bodyweight gain vs BI:10

Premix insulin: +0.8 kg to +5.4 kg
BI: +0.1 kg to +3.5 kg

Increased hypoglycemia risk vs BI10

Premix insulin: 3.4 to 8.2 events PPY
BI: 0.7 to 5.4 events PPY

Abbreviations

T2D, type 2 diabetes BI, basal insulin; IDMPS, International Diabetes Management Practices Study, LMIC, low-to-middle income country; THIN, The Health Improvement Network.BiAsp; CoDiC, Computerized Diabetes Care, Japan Diabetes Clinical Data Management Study Group; BI, basal insulin; PPY, per-patient-year

References

  1. Khunti K, et al. Diabet Res Clin Pract 2018;137:137-148.
  2. Aschner P, et al. Diabetologia. 2020;63(4):711-721.
  3. Jude EB, et al. Diabet Obes Metab 2020. doi: 10.1111/dom.14298.
  4. Ramachandran A et al. Diabetologia 2019;62:S425.
  5. Satoh J et al. PLoS One 2018;13:e0198160.
  6. Davies MJ, et al. Diabetes Care 2018;41(12):2669-2701.
  7. American Diabetes Association. Diabetes Care 2021;44(Supplement 1):S111-S124.
  8. National Institute for Clinical Excellence (NICE). Available from https://www.nice.org.uk/guidance/ng28/resources/-type-2-diabetes-in-adults-management-pdf-1837338615493 [Accessed 30 June 2020].
  9. Polinski JM, et al. BMC endocrine disorders 2015;15:46. 10. Ilag LL, et al. Clinical Ther 2007;29 Spec No:1254-1270.
MAT-BH-2300653/v1/October 2023